Sarepta Therapeutics is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $97.19 – a decrease of 2.51% over the previous week. Sarepta Therapeutics employs 1,372 staff and has a trailing 12-month revenue of around $1.9 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $97.19 |
|---|---|
| 52-week range | $97.06 - $173.25 |
| 50-day moving average | $112.13 |
| 200-day moving average | $125.95 |
| Wall St. target price | $178.55 |
| PE ratio | 41.5342 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $2.34 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $97.19 from 2025-03-14
| 1 week (2025-03-07) | -5.67% |
|---|---|
| 1 month (2025-02-14) | -9.97% |
| 3 months (2024-12-17) | -22.72% |
| 6 months (2024-09-17) | -22.67% |
| 1 year (2024-03-15) | -21.02% |
|---|---|
| 2 years (2023-03-17) | -20.78% |
| 3 years (2022-03-17) | 22.82% |
| 5 years (2020-03-17) | 11.96% |
Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sarepta Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Sarepta Therapeutics shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sarepta Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $255.8 million.
The EBITDA is a measure of a Sarepta Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.9 billion |
|---|---|
| Operating margin TTM | 24.56% |
| Gross profit TTM | $778.4 million |
| Return on assets TTM | 3.77% |
| Return on equity TTM | 19.71% |
| Profit margin | 12.37% |
| Book value | $15.77 |
| Market Capitalization | $9.4 billion |
TTM: trailing 12 months
We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.
Sarepta Therapeutics's shares were split on a 1:6 basis on 11 July 2012 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.
Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $97.06 up to $173.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 0.788. This would suggest that Sarepta Therapeutics's shares are less volatile than average (for this exchange).
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc. ; University of Western Australia; Catalent Maryland, Inc.
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
Arrived offers a simple way to invest in real estate rental properties.
3 Northwestern Mutual wealth management alternatives to consider.
Investing in mutual funds offers instant diversification. Learn more.
What you need to know about investing in the leading indicator for the overall US stock market.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.